The use of transformed Escherichia coli for experimental angiogenesis induced by regulated in situ production of vascular endothelial growth factor--an alternative gene therapy.

@article{Celec2005TheUO,
  title={The use of transformed Escherichia coli for experimental angiogenesis induced by regulated in situ production of vascular endothelial growth factor--an alternative gene therapy.},
  author={Peter Celec and Roman Gardlik and Roland P{\'a}lffy and J{\'u}lius Hodosy and Stanislav Stuchl{\'i}k and Hana Drahovsk{\'a} and Martina Stuchl{\'i}kov{\'a} and Gabriel Min{\'a}rik and J{\'a}n Luk{\'a}cs and Ingrid Jurkovi{\vc}ov{\'a} and Ivan Hul{\'i}n and Jan Turna and J{\'a}n Jakubovsk{\'y} and Martin Kop{\'a}ni and L'ubo{\vs} Dani{\vs}ovi{\vc} and D{\'a}vid Jandz{\'i}k and Mat{\'u}{\vs} K{\'u}dela and Yoshikazu Yonemitsu},
  journal={Medical hypotheses},
  year={2005},
  volume={64 3},
  pages={505-11}
}
BACKGROUND Defects in angiogenesis (blood vessel formation) are responsible for two most important causes of death in developed countries (ischemic heart disease and cancer). Vascular endothelial growth factor (VEGF) plays a pivotal role in physiological and pathological regulation of angiogenesis. In the last years several studies have indicated the possibilities of VEGF in the therapy of ischemic heart disease. However, especially VEGF gene therapy (naked DNA, plasmids and adenovirus mediated… CONTINUE READING